According to the Zhitong Finance App, Beijing Health (02389) announced its 2023 results, with revenue of about HK$140 million, a year-on-year decrease of 15.7%; parent company owners should have accounted for a loss of HK$61.882 million, a year-on-year decrease of 36.66%; and a loss of 1.01 HK cents per share.

According to the announcement, the decline in revenue was mainly due to an 18.5% decrease in sales revenue of medical products to HK$128.6 million. The main customer source for the Healthcare Products Division comes mostly from tender orders from enterprises and institutions. The cycle from winning the bid to delivery of the product is about half a year to one year. Due to the fact that in the second half of 2022, China is still in a semi-closed state under the influence of the COVID-19 pandemic, the Group's order reserves were relatively reduced, resulting in a decline in revenue carried over this year.